Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Po
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
02:05pm, Monday, 18'th May 2026
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
12:00pm, Wednesday, 13'th May 2026
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May 13, 2026
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
11:49am, Wednesday, 13'th May 2026
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story
09:46am, Wednesday, 13'th May 2026
Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine company with a clear commercial bridge. BEAM's $1.2B cash position supports a runway into mid-2029, enabl
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
07:00am, Wednesday, 13'th May 2026
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
01:11pm, Friday, 08'th May 2026
Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and PKU programs.
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
09:56am, Thursday, 07'th May 2026
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $1.24 per share a year ago.
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
07:00am, Thursday, 07'th May 2026
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort
Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM
02:10pm, Wednesday, 29'th Apr 2026
Concurrent Investment Advisors LLC acquired a new stake in Beam Therapeutics Inc. (NASDAQ: BEAM) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Comm
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
08:27am, Wednesday, 29'th Apr 2026
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Ondas Inc (NASDAQ:ONDS) is losing a lot of money and added that he would rather have to find something new and different that is distinct, wh
3 Biotech Stocks That Could Benefit from the Patent Cliff
07:06am, Monday, 27'th Apr 2026
Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.
Colossal’s Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here’s His Solution
08:49am, Sunday, 12'th Apr 2026
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That's according to Ben Lamm, CEO of Colossal Biosciences. On episode 245 of
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.
09:20am, Saturday, 11'th Apr 2026
CEO John Evans sold 30,078 company shares for a transaction value of ~$739,000 on April 1, 2026. The sale represented 2.5% of his direct holdings.
